Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Market Cap	187.67B
Revenue (ttm)	40.47M
Net Income (ttm)	-545.92M
Shares Out	1.55B
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	46.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,312,964
Average Volume	17,788,044
Open	121.50
Previous Close	123.50
Day's Range	119.00 - 124.00
52-Week Range	43.60 - 147.50
Beta	1.22
RSI	48.29
Earnings Date	Aug 11, 2025

About ATSG

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6919

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.